2026年10月6日，直觉外科盘中上涨3.07%，报404.0美元。消息面上，Evercore ISI将公司股价目标从375美元上调至400美元并维持评级，此举提振了市场对该股的信心。
分析师报告强调目标价调整反映长期价值，FactSet统计显示公司平均目标价达479.86美元，凸显市场对其在机器人手术领域领导地位的认可。
直觉外科公司成立于1995年11月9日，是机器人辅助微创护理领域的全球领导者，提供包括达芬奇手术系统和离子腔内系统在内的综合生态系统。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.